---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-239246"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-05-26T20:05:16+00:00"
generated_at: "2026-05-26T20:50:39.516726+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Viridian inks commercial manufacturing deal with WuXi Biologics for veligrotug

## Summary
- Agreement covers long-term supply of veligrotug drug substance and drug product, if approved.
- WuXi Biologics is non-exclusive supplier; Viridian may use alternate manufacturers.
- Initial term of 5 years, auto-renewing for successive 5-year periods unless 24-month non-renewal notice given.
- Volume-based pricing fixed through Dec 31, 2026, then annually adjustable; pass-through costs reimbursed.
- Company may terminate on 30 days' notice for change in law materially impacting WuXi's performance.

## SEC filing metadata
- accession: 0001193125-26-239246
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-05-26T20:05:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/0001193125-26-239246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/d111034d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-239246
- JSON: https://secwatch.observer/filing/0001193125-26-239246.json
- Plain text: https://secwatch.observer/filing/0001193125-26-239246.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.